BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $201,544 | -86.9% | 2,469 | -86.7% | 0.01% | -89.0% |
| Q4 2022 | $1,535,269 | +19.7% | 18,524 | +309.9% | 0.10% | +8.7% |
| Q3 2022 | $1,283,000 | -21.4% | 4,519 | -4.1% | 0.09% | -11.5% |
| Q2 2022 | $1,633,000 | -27.7% | 4,710 | -9.7% | 0.10% | +9.5% |
| Q1 2022 | $2,258,000 | -24.5% | 5,214 | -9.9% | 0.10% | -3.1% |
| Q4 2021 | $2,992,000 | -6.8% | 5,784 | -12.7% | 0.10% | -9.3% |
| Q3 2021 | $3,212,000 | -18.0% | 6,629 | -23.8% | 0.11% | -18.2% |
| Q2 2021 | $3,916,000 | +14.9% | 8,697 | -2.5% | 0.13% | +0.8% |
| Q1 2021 | $3,408,000 | -0.4% | 8,924 | -17.2% | 0.13% | -12.7% |
| Q4 2020 | $3,423,000 | +38.5% | 10,779 | +8.0% | 0.15% | +18.1% |
| Q3 2020 | $2,472,000 | -7.0% | 9,979 | -0.8% | 0.13% | -14.2% |
| Q2 2020 | $2,658,000 | +65.2% | 10,064 | +18.6% | 0.15% | +22.3% |
| Q1 2020 | $1,609,000 | -40.3% | 8,483 | -30.9% | 0.12% | +3.4% |
| Q4 2019 | $2,695,000 | +21.2% | 12,279 | +8.1% | 0.12% | +4.5% |
| Q3 2019 | $2,223,000 | -16.7% | 11,361 | -11.3% | 0.11% | -11.8% |
| Q2 2019 | $2,670,000 | -4.4% | 12,808 | -9.0% | 0.13% | -5.2% |
| Q1 2019 | $2,793,000 | +52.6% | 14,067 | +11.2% | 0.13% | +18.6% |
| Q4 2018 | $1,830,000 | -47.4% | 12,645 | -25.8% | 0.11% | -14.4% |
| Q3 2018 | $3,481,000 | +42.7% | 17,053 | +3.5% | 0.13% | +36.1% |
| Q2 2018 | $2,439,000 | -6.8% | 16,483 | -4.8% | 0.10% | -6.7% |
| Q1 2018 | $2,616,000 | +13.3% | 17,319 | -2.8% | 0.10% | +16.9% |
| Q4 2017 | $2,308,000 | -1.7% | 17,816 | -8.3% | 0.09% | -9.2% |
| Q3 2017 | $2,349,000 | +11.5% | 19,435 | +8.4% | 0.10% | +3.2% |
| Q2 2017 | $2,107,000 | +2.3% | 17,936 | -11.4% | 0.10% | +3.3% |
| Q1 2017 | $2,059,000 | -3.6% | 20,252 | -2.4% | 0.09% | -6.1% |
| Q4 2016 | $2,135,000 | -16.9% | 20,759 | -11.5% | 0.10% | -19.7% |
| Q3 2016 | $2,570,000 | -3.9% | 23,467 | -1.0% | 0.12% | -6.2% |
| Q2 2016 | $2,674,000 | +15.5% | 23,713 | -3.2% | 0.13% | +8.3% |
| Q1 2016 | $2,316,000 | -17.4% | 24,501 | -21.4% | 0.12% | -9.8% |
| Q4 2015 | $2,805,000 | +4.0% | 31,170 | +6.8% | 0.13% | -13.6% |
| Q3 2015 | $2,698,000 | -14.2% | 29,184 | -8.6% | 0.15% | +18.5% |
| Q2 2015 | $3,145,000 | -5.8% | 31,943 | -4.0% | 0.13% | 0.0% |
| Q1 2015 | $3,337,000 | +22.3% | 33,271 | +12.6% | 0.13% | +16.1% |
| Q4 2014 | $2,729,000 | – | 29,540 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |